Results for kasvajavastane translation from Estonian to English

see on kasvajavastane raviaine.
this medicine is an antitumour agent.

temodal on kasvajavastane preparaat.
temodal is an antitumour agent.

alustamist tuleb lõpule viia kasvajavastane ravi;
therapy must be completed prior to starting therapy.

selle kasvajavastane toime arvatakse tulenevat 3 mehhanismist:
its antitumour activity is believed to be due to 3 mechanisms:

kasvajavastane aktiivsus leidis tõestust peamiselt neuroblastoomiga patsientidel.
antitumour activity was demonstrated primarily in patients with neuroblastoma.

loommudelites on gemtsitabiini kasvajavastane aktiivsus sõltuv manustamise sagedusest.
antitumoral activity in preclinical models in animal tumour models, antitumoural activity of gemcitabine is schedule-dependent.

ja kasvajavastane ravi peab olema lõpetatud enne kasvuhormooniga ravimise algust.
therapy complete prior to the institution of growth hormone therapy.

- tseftriaksooni keemilisest kokkusobimatusest on samuti teatatud amsakriini (kasvajavastane
- a chemical intolerance of ceftriaxone has also been reported with amsacrine (antitumour agent),

in vivo kasvajavastane aktiivsus põhineb arvatavasti nii otsestel kui kaudsetel toimetel.
in vivo antitumour activity is probably based on direct and indirect effects.

kabasitakseel on kasvajavastane aine, mis toimib, häirides rakkude mikrotubulaarset võrgustikku.
cabazitaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells.

krisotiniibi kasvajavastane efektiivus oli annusest sõltuv ja korreleerus ros1 fosforüleerimise pärssimisega in vivo.
the antitumour efficacy of crizotinib was dose-dependent and demonstrated a correlation with inhibition of ros1 phosphorylation in vivo.

enne gh ravikuuri alustamist peavad intrakraniaalsed kasvajad olema passiivsed ja tuleb lõpule viia kasvajavastane ravi.
intracranial tumours must be inactive and anti-tumour therapy must be completed prior to starting gh therapy.

tasonermiin kuulub ühendite klassi, mida tuntakse bioloogilise vastuse modifitseerijatena ja millel on kasvajavastane toime.
tasonermin belongs to a class of compounds known as biological response modifiers and has been demonstrated to have anti-tumour activity.

enne kasvuhormooni ravikuuri alustamist peavad intrakraniaalsed kasvajad olema inaktiivsed ja kasvajavastane ravi peab olema lõpule viidud.
intracranial tumours must be inactive and antitumour therapy must be completed prior to the initiation of growth hormone therapy.

eksperimentaalsed uuringud lubavad oletada, et tselekoksiibi kasvajavastane toime võib olla seotud apoptoosi esilekutsumisega ning angiogeneesi pärssimisega.
experimental evidence shows that the mechanism(s) of action by which celecoxib leads to tumour death may be related to induction of apoptosis and inhibition of angiogenesis.

tsütarabiin on rakutsükli suhtes spetsiifiline kasvajavastane aine, mis toimib rakkudele ainult rakujagunemise käigus s-faasis.
cytarabine is a cell-cycle phase specific antineoplastic agent, affecting cells only during the s-phase of cell division.

farmakoterapeutiline rühm: kasvajavastane aine, fotodünaamilises ja kiiritusravis kasutatavad sensibileerivad ained, atc-kood: l01xd04
pharmacotherapeutic group: antineoplastic agent, sensitizers used in photodynamic/radiation therapy, atc code: l01xd04

topotekaani kasvajavastane toime põhineb dna replikatsioonis vahetult osaleva ensüümi topoisomeraas-i inhibeerimisel, mis leevendab enne replikatsioonihargnemist tekkinud torsioonipinget.
the anti-tumour activity of topotecan involves the inhibition of topoisomerase-i, an enzyme intimately involved in dna replication as it relieves the torsional strain introduced ahead of the moving replication fork.

prekliinilistes uuringutes on ilmnenud regorafeniibi tugev kasvajavastane toime paljudes kasvajamudelites, sh kolorektaalse ja gastrointestinaalse stromaalkasvaja mudelites, mida vahendavad aine antiangiogeensed ja proliferatsioonivastased toimed.
in preclinical studies regorafenib has demonstrated potent antitumour activity in a broad spectrum of tumour models including colorectal and gastrointestinal stromal tumour models which is mediated by its anti-angiogenic and anti-proliferative effects.

doksorubitsiini kasvajavastane ja toksiline mõju võib avalduda mitme mehhanismi kaudu, sh topoisomeraas ii inhibeerimine, interkaleerumine dna ja rna polümeraasidega, vabade radikaalide teke ja membraaniga seondumine.
doxorubicin may exert its antitumour and toxic effects by a number of mechanisms including inhibition of topoisomerase ii, intercalation with dna and rna polymerases, free radical formation and membrane binding.